Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review.

"the search string was adapted to each database (the full search string of each database is shown in data s1 ).; data s1."

"CONFLICT OF INTEREST STATEMENT The authors Dethlefsen, Holdt‐Caspersen, and Jensen are employees of Novo Nordisk and hold shares herein. Peter Vestergaard is the Head of Research at Steno Diabetes Center North Denmark funded by the Novo Nordisk Foundation."

"FUNDING INFORMATION This work was supported by a research grant from the Danish Diabetes and Endocrine Academy, which is funded by the Novo Nordisk Foundation, grant number NNF17SA0031406."

"A systematic literature search was performed to identify studies, which investigated the adherence to newer second‐line OADs. The search was performed on the 12 and 13 July 2022 and included articles published from 2012 to the search date. The protocol of the systematic literature search was preregistered on PROSPERO (registration ID: CRD42022344503)."